| Description | Rapacuronium bromide is an allosteric muscarinic acetylcholine receptor (mAChR) modulator. |
| In vitro | Rapacuronium accelerates the rate of ACh binding but decreases its affinity under equilibrium conditions.?This results in potentiation of receptor activation at low concentrations of rapacuronium (1 microM) but not at high concentrations (10 microM).?These observations highlight the relevance and necessity of performing physiological tests under non-equilibrium conditions in evaluating the functional effects of allosteric modulators at muscarinic receptors. |
| In vivo | Time course of the neuromuscular effects of Rapacuronium following the administration of the 2×ED90 doses to rats and guinea-pigs(ED90 of 5953±199 and 187±16 μg/kg in rat and guinea pig, respectively)[2]. |
| Synonyms | Org 9487 |
| molecular weight | 677.8 |
| Molecular formula | C37H61BrN2O4 |
| CAS | 156137-99-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 125 mg/mL (184.42 mM) |
| References | 1. Jakubík J, et al. Divergence of allosteric effects of Rapacuronium on binding and function of muscarinic receptors. BMC Pharmacol. 2009 Dec 28;9:15. 2. Vizi ES, et al. A new short-acting non-depolarizing muscle relaxant (SZ1677) without cardiovascular side-effects. Acta Anaesthesiol Scand. 2003 Mar;47(3):291-300. |